Clinical Trial Update: Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of weekly motexafin gadolinium (Xcytrin) in chronic lymphocytic leukemia and small lymphocytic lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Xcytrin (motexafin gadolinium)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: COMPLETED